Drugs / DS-9606a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05394675 | May 2022 → Feb 2026 | germ cell tumor, metastatic malignant neoplasm | Daiichi Sankyo | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-9606a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05394675 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05394675 ↗ |
| Target | CLDN6 | “anti-CLDN6 ADC” NCT05394675 ↗ |